Satellite Symposia

Werfen, 22 April 2026, 13:00–14:00, Fintry Hall
Title: Enhancing Confidence in HLA Decision-Making: Today & Tomorrow
 
Two Platforms, Two Suppliers: Evaluating Variability in Anti-HLA Antibody Detection
Marie-Joelle Apithy, Établissement français du sang, Strasbourg, France

NanoTYPETM HLA-11 Plus: A multicenter clinical validation & user experience
Maja Norgaard, Aarhus Universitetshospital, Denmark

Hansa Biopharma, 22 April 2026, 14:00–15:00, Fintry Hall
Title: Redefining Possibility: Advances and Strategies in HLAIncompatible Kidney Transplantation
Chair: Kay Poulton (Professor & Consultant Scientist Transplantation Laboratory, Manchester Royal Infirmary, UK)
 
Current Outcomes in HLA-Incompatible Kidney Transplantation: Where Are We Today?
Olivia Shaw, Director, Clinical Transplantation Laboratory, Clinical Transplantation Department, UK
Guy’s Hospital, London, UK

Innovations in HLAi Transplantation: Expanding the Horizons of Delisting
Jean-Luc Taupin, Professor, Immunology & Histoincompatibility, Saint-Louis Hospital – AP-HP, Paris, France

Navigating Antibody Challenges: Strategies for Transplantation in the Presence of DSA
Eduard Palou, Consultant Immunologist & Head of Transplant Laboratory, Clinic Hospital de, Barcelona, Spain

Insight Molecular Diagnostics (iMDx) – Oncocyte, 22 April 2026, 14:00–15:00, Kilsyth
Title: Real-World Evaluation of an In-House dd-cfDNA Assay: A Single-Center Validation Study at One of the World’s Largest Kidney Transplant Centers
 
Comparison of GraftAssureIQ performance to commercially available NGS-based solutions used in post-transplantation monitoring

Study design, implementation considerations, and key findings

The role of in-house dd-cfDNA testing in advancing transplant research
Suzane Silbert, PhD, Director, Esoteric Testing, R&D and Microbiology Laboratories Tampa General Hospital
Luciano Soares, PhD, Clinical Scientist Tampa General Hospital

GenDx, 23 April 2026, 12:00–13:00, Pentland
Title: From Sequencing to Success: Innovation Across the Transplant Journey
 
Closing the Gaps in Post Transplant Monitoring: The Power of HLA Loss Testing
Arthi Anand, Consultant Clinical Scientist at Imperial College Healthcare NHS Trust

High-Resolution HLA Typing in Solid Organ Transplantation
Dr. Cynthia Kramer, Scientist at GenDx

CareDx, 23 April 2026, 13:00–14:00, Sidlaw Auditorium
Title: Together in Patient Care: Advancing Transplant Outcomes with AlloSeq Nano and AlloSeq cfDNA

AlloSeq Nano: Robust High-Resolution HLA and ABO Genotyping with Long-read Sequencing
Curtis Lind, VP, Head of Research & Development, CareDx, USA

Donor-Derived cfDNA Testing in the Laboratory Setting for Solid Organ Transplant Monitoring
Anais Certain, MSc, Institute for Transplantation & Organ Regeneration (PITOR) - PARCC - INSERM U970, France

From Test Result to Clinical Decision: Contextualizing dd cfDNA Testing in Kidney Transplantation
Prof. Dr. Maarten Naesens, Clinical Director, Nephrology & Renal Transplantation, University Hospitals Leuven (UZ Leuven), Belgium

Q&A

BAG Diagnostics, 23 April 2026, 14:00–15:00, Fintry Hall
Title: Assessing the BAG Diagnostics HISTO SPOTR HLA AB System for usability and potential integration into the Laboratory’s HLA Antibody Screening and Identification Strategy for Solid Organ and Haematopoietic Stem Cell Transplantation

Chair: Dr. Kristin Launhardt
Ella Gorton (Anthony Nolan)